Trupanion, Inc. (NASDAQ:TRUP) is a leading provider of medical insurance for pets, focusing on cats and dogs. Operating across the United States, Canada, Puerto Rico, and Australia, Trupanion offers services to both pet owners and veterinarians. Since rebranding from Vetinsurance International, Inc. in 2013, the company has established its headquarters in Seattle, Washington.
The consensus price target for Trupanion has shown a downward trend over the past year, decreasing from an average of $51.75 to $46.67 last quarter, and further to $40 last month. This suggests that analysts have become more cautious about Trupanion's stock performance. However, recent developments indicate a potential shift in sentiment.
Trupanion's stock is currently displaying a hammer chart pattern, which suggests that it may have found support after a decline. This technical indicator, along with an upward trend in earnings estimate revisions, points to a potential trend reversal. Analyst John Barnidge from Piper Sandler has set a price target of $156 for Trupanion, indicating a positive outlook for the stock.
Trupanion's recent Q3 2025 earnings call provided insights into its financial performance. The company reported earnings of $0.13 per share, surpassing the Zacks Consensus Estimate of $0.06 per share. This marks a significant improvement from the $0.03 per share reported in the same quarter last year. The positive earnings report has contributed to growing optimism about Trupanion's future prospects.
Trupanion has also received a boost in investor confidence following its upgrade to a Zacks Rank #1 (Strong Buy). This upgrade reflects growing optimism about the company's earnings prospects. As highlighted by analyst John Barnidge from Piper Sandler, the price target of $156 suggests a positive outlook for Trupanion's stock performance in the future.
